US EditionDM Clinical Research Partners with Florida Sleep Specialists to Advance Sleep and Obesity Medicine Research
- DM Clinical Research partnered with Dr. Jeremy McConnell of Florida Sleep Specialists on April 15, 2025, in Bradenton.
- DM Clinical Research seeks to enhance patient care and streamline trials, aligning with Dr. McConnell's focus.
- This collaboration establishes a new embedded research site and expands DM Clinical Research's network.
- CEO Mohammad Millwala stated the partnership will advance research and patient care, integrating capabilities to help patients.
- The partnership aims to improve trial access, deliver quality data, and provide innovative obesity solutions in the region.
27 Articles
27 Articles
Does lack of sleep hold you back on the running track? Here’s the research
Research is mounting showing that a lack of sleep will hold you back from maximizing your fitness potential. Poor sleep negatively affects your pace and performance. The post Does lack of sleep hold you back on the running track? Here’s the research appeared first on The Manual.
Bennington Banner
DM Clinical Research Partners with Florida Sleep Specialists to Advance Sleep and Obesity Medicine Research
BRADENTON, Fla., April 15, 2025 /PRNewswire/ -- DM Clinical Research, a leading multi-therapeutic site network, has partnered with Dr. Jeremy McConnell, founder of Florida Sleep Specialists to establish an embedded clinical research site in Bradenton, Florida. Dr. McConnell's expertise expands…
U.S. Phase 2 trial aims to evaluate the efficacy and safety of CX11 at doses up to 200 mg and at different titration regimens The trial is expected to enroll 250 patients for 36 weeks of treatment (SeaPRwire) – BERKELEY HEIGHTS, NJ, April 15, 2025 — Corxel Pharmaceuticals Limited (CORXEL) is a clinical-stage biopharmaceutical company developing innovative therapies for patients suffering from cardiometabolic diseases worldwide. Today, the comp…
Corxel to begin trial of CX11 for obesity with FDA clearance
Corxel Pharmaceuticals has received investigational new drug (IND) application clearance from the US FDA for the trial of CX11 for obesity.The post Corxel to begin trial of CX11 for obesity with FDA clearance appeared first on Clinical Trials Arena.
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
